

October 1, 2020

Re: Anthem prior authorization updates for specialty pharmacy are available

Dear Provider:

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Nevada (Anthem), is writing to inform you of the following authorization updates for specialty pharmacy.

Prior authorization updates

Effective for dates of service on and after January 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

Please note, inclusion of NDC code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

To access the Clinical Criteria information please click [here](https://www11.anthem.com/pharmacyinformation/clinicalcriteria.html). (Or go directly to URL: www11.anthem.com/pharmacyinformation/clinicalcriteria.html)

Anthem's prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem's medical specialty drug review team. *Review of specialty pharmacy drugs for oncology indications will be managed by AIM Specialty Health® (AIM), a separate company and are shown in italics in the table below.*

Clinical Criteria	HCPCS or CPT Code(s)	Drug
<i>*ING-CC-0002</i>	<i>J3590</i>	<i>Nyvepria</i>
ING-CC-0015	J3490	Milprosa Vaginal System
<i>*ING-CC-0019</i>	<i>J3489</i>	<i>Zoledronic acid, 1 mg</i>
<i>*ING-CC-0026</i>	<i>J3145</i>	<i>Testosterone undecanoate, 1 mg</i>
ING-CC-0038	J3110	Forteo
<i>*ING-CC-0053</i>	<i>J1726</i>	<i>Hydroxyprogesterone caproate (Makena), 10 mg</i>
<i>*ING-CC-0100</i>	<i>C9065</i>	<i>Istodax</i>
ING-CC-0168	J3590, J9999, J3490	Tecartus
<i>*ING-CC-0169</i>	<i>J3490, J3590, J9999, C9399</i>	<i>Phesgo</i>
ING-CC-0170	J3590, C9399	Uplizna
<i>*ING-CC-0171</i>	<i>J3490, J3590, J9999</i>	<i>Zepzelca</i>
ING-CC-0172	J3490, J3590, C9399	Viltepso
ING-CC-0173	J3490, J3590	Enspryng
ING-CC-0174	J3490, J3590, C9399	Kesimpta
<i>*ING-CC-0175</i>	<i>J9015</i>	<i>Proleukin</i>
<i>*ING-CC-0176</i>	<i>J9032</i>	<i>Beleodaq</i>
<i>*ING-CC-0177</i>	<i>J3304</i>	<i>Zilretta</i>
<i>*ING-CC-0178</i>	<i>J9262</i>	<i>Synribo</i>

* Non-oncology use is managed by Anthem's medical specialty drug review team. *Oncology use is managed by AIM.*

Step therapy updates

Effective for dates of service on and after January 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our existing specialty pharmacy medical step therapy review process.

To access the Clinical Criteria information related to Step Therapy, please click [here](#).
(Or go directly to URL: www11.anthem.com/pharmacyinformation/clinicalcriteria.html)

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. *Review of specialty pharmacy drugs for oncology indications will be managed by AIM Specialty Health® (AIM), a separate company and are shown in italics in the table below.*

Clinical Criteria	Status	Drug(s)	HCPCS Code(s)
<i>*ING-CC-0002</i>	<i>Preferred</i>	<i>Neulasta</i>	<i>J2505</i>
<i>*ING-CC-0002</i>	<i>Preferred</i>	<i>Udenyca</i>	<i>Q5111</i>
<i>*ING-CC-0002</i>	<i>Non-preferred</i>	<i>Fulphila</i>	<i>Q5108</i>
<i>*ING-CC-0002</i>	<i>Non-preferred</i>	<i>Ziextenzo</i>	<i>Q5120</i>
<i>*ING-CC-0002</i>	<i>Non-preferred</i>	<i>Nyvepria</i>	<i>J3590</i>

** Non-oncology use is managed by Anthem’s medical specialty drug review team.
Oncology use is managed by AIM.*

We value and appreciate you as our partner in providing quality care, and appreciate your continued participation in our network.

Sincerely,



Jo Ann Nishimoto, MD
Medical Director
Anthem Blue Cross and Blue Shield